Grant opportunity · PAR-25-225
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Who can apply (as listed)
- County governments
- Native American tribal organizations (other than federally recognized governments)
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Public and state-controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Special district governments
- For-profit organizations (other than small businesses)
- State governments
- Private institutions of higher education
- Small businesses
- Others (see the opportunity text)
- City or township governments
- Independent school districts
- Native American tribal governments (federally recognized)
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.